You are currently viewing Resolute pooled data in bifurcation lesions

Resolute pooled data in bifurcation lesions


European Bifurcation Club 2011, EBC 2011 – Lisbon, Portugal


Resolute pooled data in bifurcation lesions

AuthorRan Kornowski, MD, Rabin Medical Center and Tel Aviv University, Israel



  • Bifurcation lesions remain a therapeutic challenge and a focus of great interest among interventional cardiologists.
  • The impact of the Resolute DES platform, with its open-cell design and unique BioLinxpolymer and Zotarolimus anti-proliferative drug, on the technical and clinical outcomes in bifurcation lesions has not been yet explored.


In the pooled dataset with Resolute bifurcation lesions we observed:

  • Excellent technical/angiographic success rate with 19.1% need for SB stenting in the treated cohort.
  • Sustainable clinical efficacy out to one year(e.g.very low rates of TLR 4.8% and TVR 6.1%).
  • Favorable TLF (10.3%) event rate with low stent thrombosis (2.0%, mostly early) up to one year.
  • Thus, the Resolute DES platform is a viable treatment option for bifurcation lesion management.


Download here

Leave a Reply